ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

CARTON

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HyperCard 10 mg Coated Tablets for Cats Diltiazem hydrochloride

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each tablet contains: 10 mg of Diltiazem hydrochloride Excipients: Tartrazine (E102) Titanium Dioxide, (E171)

0.11 mg

3. PHARMACEUTICAL FORM

Coated tablets.

4. PACKAGE SIZE

30 tablets.

5. TARGET SPECIES

Cats.

6. INDICATION(S)

For the therapeutic treatment of feline primary hypertrophic cardiomyopathy.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For oral administration.

1 tablet per cat (weighing 3.0 - 6.25 kg bodyweight) every eight hours.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Do not use in animals suffering from AV block (2nd or 3rd), hypotension or sick sinus syndrome.

Do not use in animals suffering from hepatic disease.

Do not use in animals suffering from renal disease.

Do not use in cats less than 12 months old.

Do not use in cats weighing less than 3 kg.

Do not use in animals that are hypersensitive to diltiazem. Do not use in cats with severe bradycardia or arterial hypotension. Do not use in conjunction with β blockers, digitalis or digoxin. Do not use in pregnant or lactating females. See package insert for further details.

10. EXPIRY DATE

EXP

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C. Keep the blister strips in the outer carton.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only.

To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"

Keep out of the reach and sight of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, UK.

16. MARKETING AUTHORISATION NUMBER(S)

UK: Vm 10434/4060 IE: VPA 10799/016/001

17. MANUFACTURER'S BATCH NUMBER

Lot

18. FURTHER INFORMATION

UK: POM-V

IE: POM

Veterinary medicinal product authorised for use in UK and IE.

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

BLISTER FOIL

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

HyperCard 10 mg Coated Tablets for Cats Diltiazem hydrochloride

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Dechra Limited - UK

3. EXPIRY DATE

EXP

4. **BATCH NUMBER**

Lot

5. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

6. FURTHER INFORMATION

UK: Vm 10434/4060 IE only: POM VPA 10799/016/001

B. PACKAGE LEAFLET

PACKAGE LEAFLET HyperCard 10 mg Coated Tablets for Cats

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:

Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, UK.

Manufacturer:

Dales Pharmaceuticals, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, UK.

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Hypercard 10 mg coated tablets for cats Diltiazem hydrochloride

3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Yellow coated biconvex tablets. Each tablet contains: Diltiazem hydrochloride 10 mg Excipients: Tartrazine (E102) (1.1 mg

0.11 mg

4. INDICATIONS

Hypercard 10 mg is indicated for the therapeutic treatment of feline primary hypertrophic cardiomyopathy. Diltiazem Hydrochloride is a benzothiazepine derivative which acts as a calcium channel blocker and exerts its effect by selectively inhibiting the inward movement of calcium ions across the cell membrane into vascular smooth muscle cells and myocardial cells.

5. CONTRAINDICATIONS

Do not use in animals suffering from AV block (2^{nd} or 3^{rd}), hypotension or sick sinus syndrome. Diltiazem should not be given to animals suffering from hepatic disease.

Do not use in animals suffering from renal disease.

Do not use in cats less than 12 months old.

Do not use in cats weighing less than 3 kg.

Do not use in animals that are hypersensitive to diltiazem.

Do not use in cats with severe bradycardia or arterial hypotension.

Do not use in conjunction with β blockers, digitalis or digoxin.

6. ADVERSE REACTIONS

If you notice any serious effects or any other effects not mentioned in this leaflet, please inform your veterinary surgeon.

Some lethargy can occur at the beginning of treatment.

May cause occasional minor gastrointestinal problems, e.g. constipation, vomiting and anorexia. Rashes, skin reactions and erythema are potential side effects of diltiazem.

Bradycardia, dyspnoea, hypotension and conduction abnormalities may occasionally occur.

In such cases treatment should be suspended.

7. TARGET SPECIES

Cats.

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration.

1 tablet per cat (weighing 3.0 - 6.25 kg bodyweight) every eight hours (equivalent to 1.6 - 3.3 mg diltiazem hydrochloride per kg every 8 hours).

Treatment should be given for the life of the animal.

9. ADVICE ON CORRECT ADMINISTRATION

None.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

Do not store above 25°C.

Do not use after the expiry date which is stated on the carton and blister after EXP. Keep the blister strips in the outer carton.

12. SPECIAL WARNINGS

Special precautions for use in animals:

Hepatic failure may increase the plasma concentration of diltiazem.

Monitor glucose levels carefully in diabetic animals.

Use with caution in cats suffering from congestive heart failure.

Cats with possible pre-existing thyroid problems or hyperthyroidism should be treated for this first and then be reassessed, prior to commencing treatment with diltiazem.

Clinical examination to assess the effectiveness of treatment should be performed after eight weeks. Cardiac rate should be monitored prior to treatment commencing and at every follow up visit.

Use during pregnancy, lactation or lay:

Do not use in pregnant or lactating females. Studies of laboratory animals have shown evidence of teratogenic and embryotoxic effects.

Interactions with other medicinal products:

Use with caution in conjunction with other calcium channel blockers, anticonvulsant drugs, immunosuppressant drugs, lithium, neuromuscular blocking agents and aminoglycoside antibiotics. Concurrent use with cimetidine or any other histamine 2 receptor antagonists may cause an increase in plasma diltiazem concentrations.

Gaseous anaesthetics such as halothane, isoflurane or enflurane have synergistic or additive effects with diltiazem, which may lead to hypotension, depressed myocardial contractile function, slow junctional rhythm and AV block. Therefore animals treated with Hypercard 10 mg and undergoing gaseous anaesthesia should be monitored closely.

Overdosage:

In case of overdosage, carry out gastric lavage and dose with activated charcoal.

For bradycardia and heart block, treat with normal saline infusion and vasopressors (atropine, dopamine or isoprenaline).

Observations in humans have indicated that treatment with calcium may be useful in treating toxicity from calcium channel blocker overdose.

Special precautions for the person administering the veterinary medicinal product to animals:

Wash hands after use as tartrazine in the colour coating may cause allergic reaction in people who are susceptible.

Do not break tablets.

In case of accidental ingestion, seek medical advice immediately and show the package insert to the physician.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.


14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

xx.xx.xxxx

15. OTHER INFORMATION

For animal treatment only. To be supplied only on veterinary prescription.

Presentation: 30 tablets in a blister pack.



Veterinary medicinal product authorised for use in UK and IE.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder:

Dechra Veterinary Products Limited, Sansaw Business Park, Hadnall, Shrewsbury, Shropshire, SY4 4AS, UK.